TrialJournal of Crohn's & colitis2025

Efficacy and safety of risankizumab in patients with moderately to severely active Crohn's disease: interim results from the SEQUENCE open-label extension study.

Laurent Peyrin-Biroulet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.